GenEditBio entered into a strategic cross-license agreement with ToolGen Inc. to accelerate development of innovative genome-editing therapeutics!
November 24, 2025 |
AEF |
Portfolio
Share :
GenEditBio have entered into a strategic cross-license agreement withToolGen Inc.to accelerate development of innovative genome-editing therapeutics!
This collaboration integrates ToolGen’s best-in-class CRISPR-Cas9 platform with GenEditBio’s industry-leading lipid nanoparticle (LNP) delivery technology to pursue a “once-and-done” treatment paradigm for diseases with high unmet medical needs.
The agreement signing was officiated by DrTian Zhu, Co-Founder and CEO of GenEditBio, and Dr Jong Sang Ryu, CEO of ToolGen. Through this agreement, both companies will jointly develop and accelerate the regulatory path beyond preclinical stage for GEB-200, an investigational in vivo gene-editing therapy targeting atherosclerotic cardiovascular disease (ASCVD).
ToolGen is a leading biotechnology company that leverages its foundational patent portfolio for CRISPR-Cas9 to drive research and business development in health science and agriculture.
At GenEditBio, we are committed to developing fundamentally safe, efficacious and affordable in vivo genome editing therapies for genetic diseases with unmet medical needs.
Once again, GenEditBio is deeply honored to partner with ToolGen and is eagerly looking forward to realizing our common goal of bringing safe and effective genome-editing therapies to patients worldwide.
